Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2017

View Archived Issues

Celgene agrees to acquire Delinia

Gene therapy GS-030 receives U.S. orphan status for retinitis pigmentosa

New trial will explore 5-ALA to prevent reduction in cardiac output after heart bypass surgery

Therapicon's melatonin formulation named U.S. orphan drug for necrotizing enterocolitis

Topline results from two pivotal phase III trials of SB-204 in patients with acne vulgaris

Ramot and Merck collaborate to develop antibody-drug conjugates for cancer

EMA's CHMP supports approval of Revlimid for post-ASCT maintenance therapy in MM

EMA committee gives positive opinion for Pfizer's Xeljanz

GreenPeptide initiates phase II trial of GRN-1201 for NSCLC in U.S.

Biogen presents promising data for the novel radiotracer MK-6240

Recordati's Cystadrops approved in E.U.

Scancell and Addario Lung Cancer Medical Institute collaborate on trials of SCIB-2

Phase Ib results for oral CC-122 in patients with advanced hepatocellular carcinoma

FDA approves Latuda to treat schizophrenia in adolescents

Amgen receives positive opinion for biosimilar adalimumab ABP-501

FDA maintains clinical hold on Regulus' RG-101 program

Topline results from phase III chronic constipation trial of linaclotide in Japan

GlaxoSmithKline discovers novel BMP-1 and TLL1/2 inhibitors

Sage Therapeutics presents new NMDA receptor ligands

Piramal Enterprises to acquire intrathecal spasticity and pain management drugs from Mallinckrodt

ViiV Healthcare UK identifies novel HIV integrase inhibitors

Research Council of Norway grant supports Bionor's development of Vacc-4x for HIV

Losartan given with FOLFIRINOX in phase II trial in locally advanced pancreatic cancer

Results from phase Ib trial of AM-0010 plus FOLFOX in metastatic pancreatic adenocarcinoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 16, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Hits’ Hyperlab launches as ‘virtual AI lab’ for new drug discovery
BioWorld Science
Things once done in laboratories can now be done with computers and AI, said Kim Woo-youn, CEO and cofounder of Hits Inc. “We live in the age of ‘digital...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...